Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. announced on June 9, 2026 (via an 8-K and attached press release) that its clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures recommended under ICH E1, the international regulatory standard for safety-database exposure recommendations for drugs intended for long-term treatment of non-life-threatening conditions.

Key Details

• Date filed: June 9, 2026 (Current Report on Form 8-K).
• Program: Fasedienol nasal spray for acute treatment of social anxiety disorder.
• Milestone: Achieved the minimum patient exposures recommended under ICH E1 (international safety-exposure guidance).
• Filing attachments: Press release included as Exhibit 99.1; report signed by Shawn K. Singh, President & CEO.

Why It Matters
Meeting the ICH E1 minimum patient-exposure threshold is a concrete regulatory-safety milestone the company has reported. ICH E1 defines exposure recommendations used internationally to assess the size of a drug’s safety database for non-life-threatening conditions. For investors, this indicates Vistagen has reached a company-disclosed development-stage benchmark for fasedienol’s safety data, which the company can reference in future regulatory interactions or program updates.